Jill Taymans - CryoCell International CFO and VP of Fin.
| CCEL Stock | USD 6.41 0.19 3.05% |
CFO
Ms. Jill M. Taymans is Chief Financial Officer and Vice President Finance of the company. She is our Vice President, Finance and Chief Financial Officer. Ms. Taymans joined the Company in April 1997 serving initially as Controller and was appointed Chief Financial Officer in May 1998 since 2001.
| Age | 55 |
| Tenure | 24 years |
| Address | 700 Brooker Creek Boulevard, Oldsmar, FL, United States, 34677 |
| Phone | 813 749 2100 |
| Web | https://www.cryo-cell.com |
Jill Taymans Latest Insider Activity
Tracking and analyzing the buying and selling activities of Jill Taymans against CryoCell International stock is an integral part of due diligence when investing in CryoCell International. Jill Taymans insider activity provides valuable insight into whether CryoCell International is net buyers or sellers over its current business cycle. Note, CryoCell International insiders must abide by specific rules, including filing SEC forms every time they buy or sell CryoCell International'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Jill Taymans over a month ago Acquisition by Jill Taymans of 10000 shares of CryoCell International at 7.35 subject to Rule 16b-3 |
CryoCell International Management Efficiency
The company has return on total asset (ROA) of 0.0376 % which means that it generated a profit of $0.0376 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 1.292 %, meaning that it created $1.292 on every $100 dollars invested by stockholders. CryoCell International's management efficiency ratios could be used to measure how well CryoCell International manages its routine affairs as well as how well it operates its assets and liabilities. At this time, CryoCell International's Return On Tangible Assets are quite stable compared to the past year. Return On Capital Employed is expected to rise to 0.08 this year, although the value of Return On Equity will most likely fall to (0.04). At this time, CryoCell International's Other Assets are quite stable compared to the past year. Return On Tangible Assets is expected to rise to 0.01 this year, although the value of Net Tangible Assets will most likely fall to (17.6 M).Similar Executives
| Found 13 records | CFO Age | ||
| Matthew Buckhalter | Aveanna Healthcare Holdings | 36 | |
| Suzanne CPA | The Ensign Group | 51 | |
| Yaw Yap | Concord Medical Services | 56 | |
| Norman Rosenberg | DocGo Inc | 55 | |
| Suzanne Snapper | The Ensign Group | 50 | |
| David CPA | Surgery Partners | 53 | |
| David Duckworth | Acadia Healthcare | 44 | |
| Brian CPA | National HealthCare | 50 | |
| David Doherty | Surgery Partners | 52 | |
| Dawn CPA | Brookdale Senior Living | 51 | |
| Michael Malatesta | Select Medical Holdings | 55 | |
| Kevin CPA | Sonida Senior Living | 44 | |
| Marc Richards | Mednax Inc | 53 | |
Management Performance
| Return On Equity | 1.29 | ||||
| Return On Asset | 0.0376 |
CryoCell International Leadership Team
Elected by the shareholders, the CryoCell International's board of directors comprises two types of representatives: CryoCell International inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CryoCell. The board's role is to monitor CryoCell International's management team and ensure that shareholders' interests are well served. CryoCell International's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CryoCell International's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mark Portnoy, Co-CEO and Director | ||
| Jill Taymans, CFO and VP of Fin. | ||
| Joanne MD, Medical Board | ||
| Oleg Mikulinsky, Chief Officer | ||
| David Portnoy, Chairman and Co-CEO |
CryoCell Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is CryoCell International a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 1.29 | ||||
| Return On Asset | 0.0376 | ||||
| Profit Margin | 0.01 % | ||||
| Operating Margin | (0.02) % | ||||
| Current Valuation | 59.71 M | ||||
| Shares Outstanding | 8.08 M | ||||
| Shares Owned By Insiders | 47.59 % | ||||
| Shares Owned By Institutions | 12.70 % | ||||
| Number Of Shares Shorted | 9.45 K | ||||
| Price To Earning | 10.76 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in CryoCell International. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For more information on how to buy CryoCell Stock please use our How to buy in CryoCell Stock guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CryoCell International. If investors know CryoCell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CryoCell International listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.625 | Dividend Share 0.25 | Earnings Share 0.05 | Revenue Per Share | Quarterly Revenue Growth 0.019 |
The market value of CryoCell International is measured differently than its book value, which is the value of CryoCell that is recorded on the company's balance sheet. Investors also form their own opinion of CryoCell International's value that differs from its market value or its book value, called intrinsic value, which is CryoCell International's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CryoCell International's market value can be influenced by many factors that don't directly affect CryoCell International's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CryoCell International's value and its price as these two are different measures arrived at by different means. Investors typically determine if CryoCell International is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CryoCell International's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.